DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies April 30, 2025
Moffitt Cancer Center Announces Strategic Collaboration With Galapagos To Transform CAR T Manufacturing in the Southeast April 30, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 8, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 2, 2025
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers March 4, 2025
Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing February 11, 2025
First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 February 11, 2025
BrainChild Bio, Inc. to clinically advance BCB-276, an autologous B7-H3 targeting CAR T-cell therapy for incurable pediatric brain tumors January 15, 2025
Investigator-initiated trial (IIT) initiated in China for KJ-C2219 for the treatment of R/R B-NHL January 7, 2025
Positive Initial Clinical Data Announced in Ph 1 Clinical Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML December 4, 2024
Positive Results from the Ongoing Clinical Trial of BTK Degrader NX-5948 in Patients with R/R Waldenstrom’s Macroglobulinemia Presented October 22, 2024
CRLs submitted to request lifting the clinical holds for zevorcabtagene autoleucel, satricabtagene autoleucel and CT071 October 15, 2024
Positive Interim Ph 1 Results for P-BCMA-ALLO1 with High ORR in Heavily Pretreated RRMM Patients Reported October 8, 2024
FDA Clears IND Application for UB-VV111, a CD19 Directed in situ CAR-T for Heme Malignancies August 6, 2024
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies July 1, 2024
EMA accepts under Accelerated Assessment of MAA for UM171 Cell Therapy for patients with heme malignancies who lack a readily available suitable donor July 1, 2024
Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Ph 1/2 Clinical Trial of MB-106 Announced June 25, 2024
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib June 18, 2024
Ph 1 Trial of Menin Inhibitor HMPL-506 Initiated in Patients with Hematological Malignancies in China June 11, 2024
First Patient Dosed in Ph 1 Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML May 21, 2024
